The clinical studies will be carried out at the Central Military Hospital, located in the Buenos Aires neighborhood of Palermo, from the first days of next month.
After the authorities of the pharmaceutical companies BioNTech and Pfeizer confirmed that Argentina is “one of the global locations” chosen to test a coronavirus vaccine, expectations began to grow of being one of the first countries to receive the doses. initials.
While awaiting the start of clinical studies to be carried out on national soil starting in August, Fernando Polack, an infectologist, scientific director of the Infant Foundation and in charge of carrying out the main investigation of vaccination trials in our country, revealed what benefit could potentially lead to being part of the evidence for a possible cure against Covid-19.
“These trials often open the door for participating countries increase their chances of accessing vaccines as soon as possible. We are proud that the scientific community in Argentina has a key role in global research efforts and in the fight against the virus “, he said to Clarín.
“Traditionally, countries that have the privilege of participating in tests of this nature tend to receive vaccine shipments with priority. That is the wish of all of us who participate in trials,” he later added, in an interview with Page 12.
Countries participating in trials usually receive the first doses
It should be noted that clinical studies will only be carried out at the Central Military Hospital, located in the Buenos Aires neighborhood of Palermo, from the first days of next month (subject to the approval of ANMAT). Those trials are intended for people over the age of 18 who were not exposed to Covid-19 since the purpose of the vaccine is to prevent the disease by generating high levels of antibodies.
In any case, beyond optimism for the eventual facilitation of the first doses -in case they work, of course-, Polack clarifies: “No company will have the initial capacity to produce vaccines to protect the entire population., and not even the initial ability to cover any of the participating countries entirely. This is why the World Health Organization has produced guidelines that allow prioritizing the groups to be vaccinated. ”
No laboratory has the capacity to manufacture the doses that the entire population needs.
It is worth noting that some of the reasons why pharmaceutical companies chose Argentina as the point to test for coronavirus vaccines have to do with “the epidemiological situation allows testing in the context of viral circulation in the community” and with that our country is one of those with “a great history of development in scientific and medical research in particular”, as indicated by Pfizer.
Likewise, although it was revealed that there is not yet a specific number of planned doses available to Argentina, at the global level it is expected that around 100 million doses will be developed by the end of this year and about 1.2 billion by the end of this year. from 2021.
Find out the latest on digital economy, startups, fintech, corporate innovation and blockchain. CLICK HERE